Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I

E. Kerwin, A. D‘Urzo, A. Gelb, H. Lakkis, E. Garcia Gil, C. Caracta (Medford, Lakewood, Jersey City, United States Of America; Toronto, Canada; Barcelona, Spain)

Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Session: Regulation of airway hyperresponsiveness and bronchodilators
Session type: Thematic Poster Session
Number: 1235
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Kerwin, A. D‘Urzo, A. Gelb, H. Lakkis, E. Garcia Gil, C. Caracta (Medford, Lakewood, Jersey City, United States Of America; Toronto, Canada; Barcelona, Spain). Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I. Eur Respir J 2010; 36: Suppl. 54, 1235

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011

Long-term efficacy of twice-daily aclidinium bromide in COPD patients: A one-year study
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010


Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015


ACCORD COPD I: Twice-daily aclidinium bromide improves quality of life and dyspnea in COPD patients
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

Twice-daily aclidinium bromide in COPD patients: A pooled analysis of lung function in the ACCORD-COPD I and ATTAIN trials
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice-daily aclidinium bromide
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


Tiotropium bromide: Efficacy and safety in complex treatment of COPD
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017

AMPLIFY: efficacy of aclidinium vs tiotropium in COPD
Source: International Congress 2018 – COPD management
Year: 2018


Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016

Pooled analysis of twice-daily aclidinium bromide in COPD patients: Dyspnea and health status in the ACCORD-COPD I and ATTAIN trials
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013


Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
Source: Eur Respir J 2012; 40: 1106-1114
Year: 2012



Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014


Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014